MA22866A1 - Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs . - Google Patents
Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs .Info
- Publication number
- MA22866A1 MA22866A1 MA23157A MA23157A MA22866A1 MA 22866 A1 MA22866 A1 MA 22866A1 MA 23157 A MA23157 A MA 23157A MA 23157 A MA23157 A MA 23157A MA 22866 A1 MA22866 A1 MA 22866A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- neuro
- compounds
- preparation
- degenerative disorders
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- FWUQWDCOOWEXRY-ZDUSSCGKSA-N lanicemine Chemical compound C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 FWUQWDCOOWEXRY-ZDUSSCGKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929207339A GB9207339D0 (en) | 1992-04-03 | 1992-04-03 | Pharmaceutical compound |
| GB929208290A GB9208290D0 (en) | 1992-04-15 | 1992-04-15 | Pharmaceutical compound having neuroprotective properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA22866A1 true MA22866A1 (fr) | 1993-12-31 |
Family
ID=26300643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA23157A MA22866A1 (fr) | 1992-04-03 | 1993-04-02 | Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs . |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0633879B1 (enExample) |
| JP (2) | JP3120810B2 (enExample) |
| KR (1) | KR100259567B1 (enExample) |
| CN (1) | CN1044367C (enExample) |
| AT (1) | ATE163925T1 (enExample) |
| AU (2) | AU3897693A (enExample) |
| CA (1) | CA2133427C (enExample) |
| CZ (1) | CZ288519B6 (enExample) |
| DE (1) | DE69317411T2 (enExample) |
| DK (1) | DK0633879T3 (enExample) |
| DZ (1) | DZ1677A1 (enExample) |
| ES (1) | ES2115055T3 (enExample) |
| FI (1) | FI105025B (enExample) |
| HU (1) | HU211529A9 (enExample) |
| IL (1) | IL105276A (enExample) |
| MA (1) | MA22866A1 (enExample) |
| MX (1) | MX9301935A (enExample) |
| MY (1) | MY110149A (enExample) |
| NO (1) | NO302170B1 (enExample) |
| NZ (1) | NZ251384A (enExample) |
| PL (1) | PL180014B1 (enExample) |
| RU (1) | RU2128650C1 (enExample) |
| SG (1) | SG47948A1 (enExample) |
| SK (1) | SK281258B6 (enExample) |
| TW (1) | TW282455B (enExample) |
| UA (1) | UA29437C2 (enExample) |
| WO (1) | WO1993020052A1 (enExample) |
| ZA (1) | ZA932415B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9320273D0 (en) * | 1993-04-01 | 1993-11-17 | Fisons Corp | Compound useful in therapy |
| EP0648489A1 (en) * | 1988-08-12 | 1995-04-19 | Fisons Corporation | Arylalkylamides having neuroprotective properties |
| ZA942140B (en) * | 1993-04-01 | 1994-10-03 | Fisons Corp | Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901237D0 (sv) * | 1999-04-06 | 1999-04-06 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| ES2250170T3 (es) * | 1999-07-28 | 2006-04-16 | Ortho-Mcneil Pharmaceutical, Inc. | Derivados de aminas y de amidas utilizados como ligando para el receptor y5 del neuropeptido y, util en el tratamiento de la obesidad y otros trantornos. |
| WO2007017652A2 (en) * | 2005-08-10 | 2007-02-15 | Astrazeneca Ab | Arylakylamines for the treatment of cancer |
| CA2748235A1 (en) * | 2008-12-24 | 2010-07-01 | Astrazeneca Ab | Ethanamine compounds and their use for treating depression |
| CN104114714A (zh) | 2011-12-14 | 2014-10-22 | 阿斯利康(瑞典)有限公司 | Gabr-a2诊断 |
| WO2015067923A1 (en) * | 2013-11-05 | 2015-05-14 | Astrazeneca Ab | Nmda antagonist prodrugs |
| AU2021297823A1 (en) * | 2020-06-23 | 2023-02-16 | Biohaven Therapeutics Ltd. | Topical formulations of (1S)-1-phenyl-2-pyridin-2-ylethanamine |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01279862A (ja) * | 1987-12-11 | 1989-11-10 | Lab Syntex Sa | 神経保護化合物 |
| EP0648489A1 (en) * | 1988-08-12 | 1995-04-19 | Fisons Corporation | Arylalkylamides having neuroprotective properties |
-
1993
- 1993-04-01 JP JP05517251A patent/JP3120810B2/ja not_active Expired - Lifetime
- 1993-04-01 CZ CZ19942409A patent/CZ288519B6/cs not_active IP Right Cessation
- 1993-04-01 KR KR1019940703465A patent/KR100259567B1/ko not_active Expired - Lifetime
- 1993-04-01 PL PL93305404A patent/PL180014B1/pl unknown
- 1993-04-01 DE DE69317411T patent/DE69317411T2/de not_active Expired - Lifetime
- 1993-04-01 EP EP93907975A patent/EP0633879B1/en not_active Expired - Lifetime
- 1993-04-01 AU AU38976/93A patent/AU3897693A/en not_active Abandoned
- 1993-04-01 CA CA002133427A patent/CA2133427C/en not_active Expired - Lifetime
- 1993-04-01 RU RU94042465A patent/RU2128650C1/ru active
- 1993-04-01 ES ES93907975T patent/ES2115055T3/es not_active Expired - Lifetime
- 1993-04-01 SK SK1177-94A patent/SK281258B6/sk not_active IP Right Cessation
- 1993-04-01 SG SG1996005610A patent/SG47948A1/en unknown
- 1993-04-01 AT AT93907975T patent/ATE163925T1/de active
- 1993-04-01 WO PCT/GB1993/000689 patent/WO1993020052A1/en not_active Ceased
- 1993-04-01 DK DK93907975T patent/DK0633879T3/da active
- 1993-04-01 UA UA94095853A patent/UA29437C2/uk unknown
- 1993-04-01 NZ NZ251384A patent/NZ251384A/en not_active IP Right Cessation
- 1993-04-02 MY MYPI93000602A patent/MY110149A/en unknown
- 1993-04-02 ZA ZA932415A patent/ZA932415B/xx unknown
- 1993-04-02 MA MA23157A patent/MA22866A1/fr unknown
- 1993-04-02 IL IL105276A patent/IL105276A/xx not_active IP Right Cessation
- 1993-04-02 MX MX9301935A patent/MX9301935A/es unknown
- 1993-04-03 DZ DZ930038A patent/DZ1677A1/fr active
- 1993-04-03 CN CN93104534A patent/CN1044367C/zh not_active Expired - Lifetime
- 1993-04-30 TW TW082103364A patent/TW282455B/zh not_active IP Right Cessation
-
1994
- 1994-09-30 NO NO943645A patent/NO302170B1/no not_active IP Right Cessation
- 1994-09-30 FI FI944546A patent/FI105025B/fi not_active IP Right Cessation
-
1995
- 1995-06-13 HU HU95P/P00192P patent/HU211529A9/hu unknown
-
1996
- 1996-12-18 AU AU75456/96A patent/AU705419B2/en not_active Expired
-
2000
- 2000-05-30 JP JP2000159319A patent/JP2000319259A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG20218A (en) | Process for preparing of substituted 3 aminoquinuclidines | |
| EP0668750A4 (en) | PEDICULAR SCREW AND INSTRUMENTS FOR REAR SPINE CORRECTION. | |
| FR2690855B1 (fr) | Adsorbants pour l'elimination de hcl et procede pour leur production et leur utilisation. | |
| BG101118A (en) | Therapeutical compounds | |
| FR2740132B1 (fr) | Procede pour la preparation de 1,1,1,3,3-pentafluoropropane | |
| MA22866A1 (fr) | Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs . | |
| EP0673384A4 (en) | POLYPEPTIDES USEFUL IN TREATING INFLAMMABLE DISEASES. | |
| MA23134A1 (fr) | Procede pour la preparation d'aryl-piperidine carbinols . | |
| CA2217513A1 (en) | Pharmaceutical agents for the treatment of alzheimer's disease | |
| MA23663A1 (fr) | Procede de preparation de formulations pharmaceutiques | |
| CA2135709A1 (en) | Melatonin derivatives for use in treating sleep disorders | |
| MA22278A1 (fr) | Procede pour le traitement de troubles respiratoires | |
| FR2700956B1 (fr) | Composition cosmetique et pharmaceutique et procede pour sa preparation. | |
| FR2733227B1 (fr) | Procede pour la preparation de 1,1-difluoroethane | |
| MA23081A1 (fr) | Procede de preparation de derives d'indolone | |
| FR2677354B1 (fr) | Procede pour la preparation d'esters d'acides racemisables. | |
| MA23953A1 (fr) | Procede nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites | |
| IL99236A0 (en) | Pharmaceutical composition for the topical treatment of psoriasis | |
| EP0643724A4 (en) | METHOD FOR PRODUCING 3-CARBONYLANDROSTA-DIEN 17-CARBOXAMIDE DERIVATIVES. | |
| FR2703286B1 (fr) | Procede d'usinage des chants de dalles de pierre et appareil le mettant en oeuvre. | |
| FR2673635B1 (fr) | Procede pour la preparation d'une composition aerosol. | |
| FR2736635B1 (fr) | Procede de preparation d'alpha,omega-bromochloroalcanes | |
| FR2696171B1 (fr) | Procede de preparation du divinylbenzene. | |
| FR2676583B1 (fr) | Procede pour la desorption d'iode de fission. | |
| FR2702769B1 (fr) | Nouveau procede de preparation d'alkylpolyosides faiblement colores. |